[go: up one dir, main page]

WO2008121160A3 - Anticorps optimisés qui ciblent cd5 - Google Patents

Anticorps optimisés qui ciblent cd5 Download PDF

Info

Publication number
WO2008121160A3
WO2008121160A3 PCT/US2007/083247 US2007083247W WO2008121160A3 WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3 US 2007083247 W US2007083247 W US 2007083247W WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
antibodies
optimized antibodies
parent antibody
alters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083247
Other languages
English (en)
Other versions
WO2008121160A2 (fr
Inventor
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of WO2008121160A2 publication Critical patent/WO2008121160A2/fr
Publication of WO2008121160A3 publication Critical patent/WO2008121160A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui ciblent CD19, les anticorps comprenant au moins une modification par rapport à un anticorps parent, la modification changeant l'affinité pour un FcgR ou changeant une fonction effectrice par comparaison avec l'anticorps parent. L'invention concerne également des procédés d'utilisation des anticorps.
PCT/US2007/083247 2006-11-21 2007-10-31 Anticorps optimisés qui ciblent cd5 Ceased WO2008121160A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86679306P 2006-11-21 2006-11-21
US60/866,793 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008121160A2 WO2008121160A2 (fr) 2008-10-09
WO2008121160A3 true WO2008121160A3 (fr) 2009-01-22

Family

ID=39808822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083247 Ceased WO2008121160A2 (fr) 2006-11-21 2007-10-31 Anticorps optimisés qui ciblent cd5

Country Status (1)

Country Link
WO (1) WO2008121160A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001409A1 (fr) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
CA2760642A1 (fr) 2009-05-01 2010-11-04 The University Of Tokyo Anticorps anti-cadherine
WO2011089211A1 (fr) * 2010-01-22 2011-07-28 Synimmune Gmbh Anticorps anti-cd133 et leurs procédés d'utilisation
CA2799595C (fr) 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Methode de synthese d'anticorps presentant des proprietes ameliorees
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
CA2974547A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine d'attachement pour antigene dependant dela concentration en ions, variantes en region de fraction cristallisable, anticorps attachant il-8 et utilisations connexes
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2020004910A (es) * 2017-11-29 2020-10-05 Magenta Therapeutics Inc Composiciones y métodos para el agotamiento de células cd5 +.
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CA3102398A1 (fr) 2018-06-03 2019-12-12 Lamkap Bio Beta Ltd. Anticorps bispecifiques diriges contre ceacam5 et cd47
CA3107383A1 (fr) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Utilisation d'un conjugue anticorps anti-cd5 -medicament (adc) dans une therapie cellulaire allogenique
EP3831849A1 (fr) 2019-12-02 2021-06-09 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
EP3915641A1 (fr) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anticorps anti-cd5 et leurs procédés d'utilisation
EP4200335A4 (fr) * 2020-08-21 2024-10-02 City of Hope Compositions d'anticorps anti-cd5 et leurs utilisations
US20240041932A1 (en) 2020-09-14 2024-02-08 Vor Biopharma Inc. Compositions and methods for cd5 modification
US20250179172A1 (en) * 2020-12-17 2025-06-05 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Cd5 antibody and use thereof
EP4055055B1 (fr) 2020-12-18 2023-11-22 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
WO2022152185A1 (fr) * 2021-01-12 2022-07-21 南京驯鹿医疗技术有限公司 Anticorps entièrement humanisé ciblant cd5
CN113105547B (zh) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
AU2023291779A1 (en) 2022-06-16 2024-10-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
EP4572772A1 (fr) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024249954A1 (fr) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Formulations et compositions de nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (fr) * 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (fr) * 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIN J H ET AL: "Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.", BLOOD 15 OCT 1991, vol. 78, no. 8, 15 October 1991 (1991-10-15), pages 2139 - 2149, XP002505318, ISSN: 0006-4971 *
CIOCA D P ET AL: "Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2002, vol. 16, no. 3, March 2002 (2002-03-01), pages 335 - 343, XP002505317, ISSN: 0887-6924 *
PERS J O ET AL: "CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2002, vol. 16, no. 1, January 2002 (2002-01-01), pages 44 - 52, XP002505316, ISSN: 0887-6924 *
STUDNICKA G M ET AL: "HUMAN-ENGINEERED MONOCLONAL ANTIBODIES RETAIN FULL SPECIFIC BINDINGACTIVITY BY PRESERVING NON-CDR COMPLEMENTARITY-MODULATING RESIDUES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 6, 1 June 1994 (1994-06-01), pages 805 - 814, XP000447301, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
WO2008121160A2 (fr) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008121160A3 (fr) Anticorps optimisés qui ciblent cd5
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2008091798A3 (fr) Anticorps de ca9 optimises et methodes d'utilisation associees
WO2008091954A3 (fr) Anticorps cd40 optimisés et leurs procédés d'utilisation
WO2008098115A3 (fr) Anti-corps igf-1r optimisés et procédés utilisant ceux-ci
WO2007044616A3 (fr) Anticorps anti-cd30 optimises
WO2009026117A3 (fr) Nouveaux composés
WO2007024846A3 (fr) Anticorps anti-il-23
WO2008036688A3 (fr) Anticorps optimisés ciblant l'antigène hm1.24
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2005092925A3 (fr) Variantes d'immunoglobuline a l'exterieur de la region fc
WO2004072266A3 (fr) Ingenierie de l'affinite des anticorps par un remplacement complementaire en serie guide par epitope
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2006130374A3 (fr) Anticorps se liant a tweak
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008094538A3 (fr) Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
WO2009081285A3 (fr) Anticorps contre le virus de l'hépatite c
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2008143697A3 (fr) Anticorps a selectivite de proteine a
WO2008140570A3 (fr) Anticorps à sélectivité de protéine a
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2006135527A3 (fr) Procedes de selection d'aptameres

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2